Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be participating in the Leerink Partners 6th Annual Global Healthcare Conference, taking place February 15–16, 2017, at the Lotte New York Palace Hotel, New York, NY. Achaogen management will present at 2:30 p.m. Eastern Time on Thursday, February 16th, 2017.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected] Source: Achaogen, Inc. (AKAO).
